Xue Chen Li
Director/Board Member bij YICHANG HEC CHANGJIANG PHARMACEUTICAL CO., LTD.
Vermogen: 6 628 $ op 30-04-2024
Profiel
Xue Chen Li is an Independent Non-Executive Director at YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
and a Director at HEC Pharm Co., Ltd.
He holds a doctorate degree from Harvard University, a graduate degree from the University of Alberta, and an undergraduate degree from Nankai University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 30-06-2023 | 4 000 ( 0.00% ) | 6 628 $ | 30-04-2024 |
Actieve functies van Xue Chen Li
| Bedrijven | Functie | Begin |
|---|---|---|
| YICHANG HEC CHANGJIANG PHARMACEUTICAL CO., LTD. | Director/Board Member | 25-09-2020 |
HEC Pharm Co., Ltd.
 HEC Pharm Co., Ltd. Pharmaceuticals: MajorHealth Technology Yichang Dongyang Changjiang Pharmaceuical Co. Ltd. manufactures pharmaceutical products. The Company mainly develops, produces, and distributes active pharmaceutical ingredients and insulins. The firm focuses on anti-virus, endocrine and metabolic diseases and cardiovascular diseases. The company was founded on August 08, 2001and is headquartered in Dongguan, China. | Director/Board Member | - |
Opleiding van Xue Chen Li
| Harvard University | Doctorate Degree |
| University of Alberta | Graduate Degree |
| Nankai University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| YICHANG HEC CHANGJIANG PHARMACEUTICAL CO., LTD. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
HEC Pharm Co., Ltd.
HEC Pharm Co., Ltd. Pharmaceuticals: MajorHealth Technology Yichang Dongyang Changjiang Pharmaceuical Co. Ltd. manufactures pharmaceutical products. The Company mainly develops, produces, and distributes active pharmaceutical ingredients and insulins. The firm focuses on anti-virus, endocrine and metabolic diseases and cardiovascular diseases. The company was founded on August 08, 2001and is headquartered in Dongguan, China. | Health Technology |
